Table 1 Patient characteristics (n = 52)
Characteristic | N (%) | |
|---|---|---|
Sex | Male | 36 (69) |
Female | 16 (31) | |
Prior nephrectomy | Yes | 45 (87) |
No | 7 (13) | |
Age at start of nivolumab | Median (range) | 67.0 (38–86) |
ECOG PS | 0 | 35 (67) |
1 | 15 (29) | |
2 | 2 (4) | |
Histologic type | Clear cell carcinoma | 42 (81) |
Non-clear cell carcinoma | 6 (11) | |
Unknown | 4 (8) | |
Treatment line of nivolumab | Second | 18 (35) |
Third line or later | 34 (65) | |
IMDC risk classification | Favorable | 8 (15) |
Intermediate | 37 (71) | |
Poor | 7 (14) | |
Number of metastatic sites | < 3 | 31 (60) |
≥3 | 21 (40) | |
CRP at baseline | < 10 mg/L | 29 (56) |
≥10 mg/L | 23 (44) | |
NLR at baseline | < 3 | 20 (39) |
≥3 | 32 (61) | |
NLR at 4 weeks | < 3 | 20 (39) |
≥3 | 31 (59) | |
unknown | 1 (2) |